Summer Sale
50% off Premium Yearly
BillionToOne (BLLN)
Financials 
Technical Analysis 
Jun 11, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
BillionToOne (BLLN-Q) has recently made headlines with an impressive IPO, highlighting its cutting-edge technology in genetic testing for early disease detection. The company's growth trajectory has been notable, with sales increasing at an annual rate of 167% since 2021 and achieving 113% revenue growth last year. The guidance for Q3 indicates a continued strong performance, with anticipated revenue growth between 112% and 120%. Furthermore, EBITDA turned positive earlier this year, solidifying its financial health. Despite these strong metrics, the stock has experienced some volatility and pullbacks, prompting some experts to suggest waiting for a more attractive entry point.
- «
- ‹
- 1
- ›
- »
BillionToOne (BLLN) Frequently Asked Questions
What is BillionToOne stock symbol?
BillionToOne is a OTC stock, trading under the symbol BLLN (previously BLLN-Q on Stockchase) on the undefined (undefined). It is usually referred to as or BLLN
Is BillionToOne a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on BLLN (previously BLLN-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PARTIAL BUY. Read the latest stock experts' ratings for BillionToOne.
Is BillionToOne a good investment or a top pick?
BillionToOne was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for BillionToOne.
Why is BillionToOne stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BillionToOne.
Is BillionToOne worth watching?
BillionToOne is covered by Stockchase experts and is worth watching.
They had an impressive IPO recently. They make genetic tests to detect diseases early. Their technology is superb and is ahead of their competition. Since 2021, sales have been rising at 167% compounded annually. Last year saw 113% revenue growth. Q3 guidance declared revenue growth at 112-120%. EBITDA turned positive earlier this year. Excellent growth and profitable. Also, they have a clean balance sheet. However, the stock has already seen a pullback, so there's volatility. Wants to see shares fall further to make it more attractive.